Q32 Bio (NASDAQ:QTTB) CEO Jodie Pope Morrison Sells 22,506 Shares of Stock

Q32 Bio Inc. (NASDAQ:QTTB) CEO Jodie Pope Morrison sold 22,506 shares of Q32 Bio stock in a transaction on Tuesday, December 2nd. The shares were sold at an average price of $3.46, for a total value of $77,870.76. Following the transaction, the chief executive officer owned 99,000 shares in the company, valued at $342,540. This represents a 18.52% decrease in their position. The sale was disclosed in a filing with the SEC, which is available through the SEC website.

Q32 Bio Price Performance

Q32 Bio stock traded down $0.09 during mid-day trading on Friday, hitting $3.53. The company’s stock had a trading volume of 197,019 shares, compared to its average volume of 1,263,479. The firm’s 50 day moving average is $2.64 and its 200 day moving average is $2.12. The company has a market cap of $43.42 million, a PE ratio of -1.02 and a beta of 0.23. Q32 Bio Inc. has a 52-week low of $1.35 and a 52-week high of $28.06.

Q32 Bio (NASDAQ:QTTB) last released its earnings results on Thursday, November 13th. The company reported ($0.60) earnings per share for the quarter, beating the consensus estimate of ($1.39) by $0.79. As a group, analysts forecast that Q32 Bio Inc. will post -12.32 EPS for the current year.

Analyst Upgrades and Downgrades

A number of equities research analysts have issued reports on QTTB shares. Wall Street Zen upgraded shares of Q32 Bio from a “sell” rating to a “hold” rating in a research report on Sunday, October 26th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Q32 Bio in a research note on Tuesday, October 14th. Two equities research analysts have rated the stock with a Buy rating, six have issued a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat, the company currently has an average rating of “Hold” and a consensus price target of $12.17.

Hedge Funds Weigh In On Q32 Bio

Several hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Marshall Wace LLP acquired a new stake in Q32 Bio in the second quarter valued at approximately $25,000. Goldman Sachs Group Inc. raised its holdings in shares of Q32 Bio by 140.9% during the 1st quarter. Goldman Sachs Group Inc. now owns 44,373 shares of the company’s stock valued at $73,000 after purchasing an additional 25,953 shares in the last quarter. Acadian Asset Management LLC bought a new position in shares of Q32 Bio during the 1st quarter valued at $50,000. Two Sigma Investments LP acquired a new stake in shares of Q32 Bio in the 3rd quarter valued at $62,000. Finally, AQR Capital Management LLC bought a new stake in Q32 Bio in the first quarter worth $68,000. Institutional investors own 31.32% of the company’s stock.

Q32 Bio Company Profile

Q32 Bio Inc, a clinical-stage biotechnology company, develops biologic therapeutics to restore healthy immune balance in patients with autoimmune and inflammatory diseases driven by pathological immune dysfunction in the United States. Its lead product candidate is ADX-097, a humanized anti-C3d monoclonal antibody fusion protein to restore complement regulation, which has completed Phase I clinical trial for the treatment of renal and other complement-mediated diseases of high unmet need, including lupus nephritis, immunoglobulin A nephropathy, complement component 3 glomerulopathy, and anti-neutrophil cytoplasmic antibody-associated vasculitis.